Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets.

ABSTRACT: To exploit highly conserved and difficult drug targets, including multipass membrane proteins, monoclonal antibody discovery efforts increasingly rely on the advantages offered by divergent species such as rabbits, camelids, and chickens. Here, we provide an overview of antibody discovery technologies, analyze gaps in therapeutic antibodies that stem from the historic use of mice, and examine opportunities to exploit previously inaccessible targets through discovery now possible in alternate species. We summarize the clinical development of antibodies raised from divergent species, discussing how these animals enable robust immune responses against highly conserved binding sites and yield antibodies capable of penetrating functional pockets via long HCDR3 regions. We also discuss the value

SUBMITTER: Banik SSR 

PROVIDER: S-EPMC10793698 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature